Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Cash from Financing Activities of $2.9 million for Q1 2026, down 97.33% quarter-over-quarter from $108.6 million in Q4 2025.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Cash from Financing Activities for 7 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $111.4 million (up 8.0% YoY), while the FY2025 annual figure was $108.5 million, up 4.82% from the prior year.
- Cash from Financing Activities eased to $2.9 million in Q1 2026 per IKT's latest filing, from $108.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $108.6 million in Q4 2025 and bottomed at -$204769.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $17.2 million across 5 years, with a median of $181954.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 259834.29% — and 2025, when it slumped 173.72%.
- Inhibikase Therapeutics' Cash from Financing Activities stood at -$204769.0 in 2022, then surged by 32.56% to -$138104.0 in 2023, then soared by 72280.72% to $99.7 million in 2024, then gained by 8.91% to $108.6 million in 2025, then tumbled by 97.33% to $2.9 million in 2026.
- Business Quant data shows IKT's Cash from Financing Activities at $2.9 million in Q1 2026, $108.6 million in Q4 2025, and -$134130.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -14,489.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14,489.00 |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 108.57 Mn |
| Sep 30, 2025 | -134,130.00 |
| Jun 30, 2025 | 31,771.00 |
| Dec 31, 2024 | 99.68 Mn |
| Sep 30, 2024 | 181,954.00 |
| Jun 30, 2024 | 3.24 Mn |
| Mar 31, 2024 | 366,999.00 |
| Dec 31, 2023 | -138,104.00 |
| Sep 30, 2023 | 70.00 |
| Jun 30, 2023 | -35,986.00 |
| Mar 31, 2023 | 8.58 Mn |
| Mar 31, 2022 | -204,769.00 |
| Sep 30, 2021 | 29,892.00 |
| Jun 30, 2021 | 41.47 Mn |
| Mar 31, 2021 | -409,662.00 |
| Dec 31, 2020 | 14.88 Mn |
| Sep 30, 2020 | -67,132.00 |
| Jun 30, 2020 | -2,450.00 |